UA116194C2 - Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном - Google Patents

Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном

Info

Publication number
UA116194C2
UA116194C2 UAA201405767A UAA201405767A UA116194C2 UA 116194 C2 UA116194 C2 UA 116194C2 UA A201405767 A UAA201405767 A UA A201405767A UA A201405767 A UAA201405767 A UA A201405767A UA 116194 C2 UA116194 C2 UA 116194C2
Authority
UA
Ukraine
Prior art keywords
antibody
human alpha
patient
specifically binds
alpha synuclein
Prior art date
Application number
UAA201405767A
Other languages
English (en)
Inventor
Хосе Салданха
Тарлохан С. Ніджар
Original Assignee
Протена Біосаєнсиз Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Протена Біосаєнсиз Лімітед filed Critical Протена Біосаєнсиз Лімітед
Publication of UA116194C2 publication Critical patent/UA116194C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Винахід належить до антитіла, яке специфічно зв'язуються з людським альфа-синуклеїном, нуклеїнової кислоти, що кодує варіабельну ділянку важкого та варіабельну ділянку легкого ланцюга такого антитіла, способу одержання антитіла. Винахід також належить до фармацевтичної композиції, що містить антитіло, способу лікування пацієнта, який має хворобу тілець Леві або перебуває під ризиком цього захворювання, та способу виявлення тілець Леві у пацієнта, що включає введення пацієнтові ефективної кількості антитіла.
UAA201405767A 2011-10-28 2012-10-26 Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном UA116194C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161553131P 2011-10-28 2011-10-28
US201261711208P 2012-10-08 2012-10-08
PCT/US2012/062290 WO2013063516A1 (en) 2011-10-28 2012-10-26 Humanized antibodies that recognize alpha-synuclein

Publications (1)

Publication Number Publication Date
UA116194C2 true UA116194C2 (uk) 2018-02-26

Family

ID=48168610

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201405767A UA116194C2 (uk) 2011-10-28 2012-10-26 Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном

Country Status (33)

Country Link
US (7) US8609820B2 (uk)
EP (2) EP2771031B1 (uk)
JP (4) JP5775974B2 (uk)
KR (1) KR101600733B1 (uk)
CN (2) CN104334184B (uk)
AU (3) AU2012328530A1 (uk)
BR (1) BR112014010198B1 (uk)
CA (1) CA2853531C (uk)
CL (1) CL2014001073A1 (uk)
CO (1) CO7020875A2 (uk)
CY (1) CY1120398T1 (uk)
DK (2) DK3378535T5 (uk)
ES (2) ES2669395T3 (uk)
FI (1) FI3378535T3 (uk)
HK (1) HK1252895A1 (uk)
HR (2) HRP20180728T1 (uk)
HU (2) HUE037811T2 (uk)
IL (2) IL232264B (uk)
LT (2) LT3378535T (uk)
MX (2) MX370234B (uk)
MY (1) MY165038A (uk)
PE (1) PE20141568A1 (uk)
PH (1) PH12014500938B1 (uk)
PL (2) PL3378535T3 (uk)
PT (2) PT3378535T (uk)
RS (2) RS63930B1 (uk)
RU (1) RU2743738C2 (uk)
SG (1) SG11201401857WA (uk)
SI (2) SI2771031T1 (uk)
SM (2) SMT202300048T1 (uk)
UA (1) UA116194C2 (uk)
WO (1) WO2013063516A1 (uk)
ZA (1) ZA201403864B (uk)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034337B2 (en) * 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US8609820B2 (en) 2011-10-28 2013-12-17 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
NZ629296A (en) 2012-01-27 2016-06-24 Prothena Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9856319B2 (en) * 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
EP3071974A2 (en) * 2013-11-19 2016-09-28 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
JP6744856B2 (ja) 2014-04-08 2020-08-19 プロセナ・バイオサイエンシズ・リミテッド α−シヌクレインを認識する抗体を含む血液脳関門シャトル
US9732148B2 (en) 2014-10-16 2017-08-15 Genentech, Inc. Anti-α-synuclein antibodies and methods of use
GB201512203D0 (en) * 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
CN109475616B (zh) 2016-06-02 2022-10-18 麦迪穆有限责任公司 针对α-突触核蛋白的抗体及其用途
US20180328943A1 (en) * 2016-09-30 2018-11-15 Enzo Biochem, Inc. Immunomodulatory compositions and methods of use thereof
AR110074A1 (es) 2016-11-15 2019-02-20 H Lundbeck As Agentes, usos y métodos para el tratamiento de la sinucleinopatía
CA3042302A1 (en) 2016-12-02 2018-06-07 Prothena Biosciences Limited Infrared assay detecting secondary structure profiles of alpha-synuclein
CN110072888B (zh) 2016-12-16 2023-07-18 H.隆德贝克有限公司 药剂、用途和方法
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
US12049493B2 (en) 2017-01-06 2024-07-30 Abl Bio Inc. Anti-alpha-synuclein antibodies and uses thereof
CA3049110A1 (en) 2017-01-06 2018-07-12 Abl Bio Inc. Anti-.alpha.-syn antibody and use thereof
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
US11220538B2 (en) 2017-05-01 2022-01-11 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against alpha-synuclein fibrils
EP3406632A1 (en) 2017-05-23 2018-11-28 S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati Ligands binding to prion protein for use in the treatment of synucleinopathies
EP3672635A4 (en) 2017-08-23 2021-05-12 The Trustees of The University of Pennsylvania MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN AND METHOD OF USING THEREOF
US12071483B1 (en) * 2017-12-14 2024-08-27 Abl Bio Inc. Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
NL2020520B1 (en) * 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
WO2020033756A1 (en) 2018-08-09 2020-02-13 F. Hoffmann-La Roche Ag Determination of parkinson's disease
TWI734279B (zh) 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
KR102444797B1 (ko) * 2019-06-14 2022-09-20 에이비엘바이오 주식회사 α-SYN/IGF1R에 대한 이중 특이 항체 및 그 용도
CR20220531A (es) 2020-04-24 2022-11-28 Hoffmann La Roche Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados
CN114516914B (zh) * 2020-11-19 2023-04-28 东莞市朋志生物科技有限公司 抗n末端脑钠肽前体的抗体和检测n末端脑钠肽前体的试剂和试剂盒
CN112710850A (zh) * 2020-12-29 2021-04-27 苏州百志生物科技有限公司 一种检测人体液中α-突触核蛋白含量的试剂盒
TWI824243B (zh) 2021-05-05 2023-12-01 國立高雄大學 一種胜肽拓印導電聚合物及其用途
CN113912712B (zh) * 2021-12-15 2022-03-08 北京凯祥弘康生物科技有限公司 抗α-突触核蛋白的单克隆抗体的制备及其应用
CN116102646A (zh) * 2023-02-13 2023-05-12 贵安新区康顺生物科技有限公司 抗人-磷酸化突触核蛋白抗体及其应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
JP2000510813A (ja) 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Ｉｌ−１２用処方
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
WO2000046750A1 (en) 1999-02-05 2000-08-10 Samsung Electronics Co., Ltd. Image texture retrieving method and apparatus thereof
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
JP2005532825A (ja) 2002-05-13 2005-11-04 アレクシオン ファーマシューティカルズ， インコーポレイテッド ベネズエラウマ脳炎ウイルスに対するヒト化抗体
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
KR101149777B1 (ko) 2002-11-29 2012-06-11 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 신규한 네오마이신 포스포트랜스퍼라제 유전자 및 고생산성 재조합 세포의 선별 방법
US7662380B2 (en) * 2003-01-22 2010-02-16 Takeda Pharmaceutical Company Limited ZAQ ligand-1 antibodies and uses thereof
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
CA2548817A1 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
US7022550B2 (en) 2004-04-07 2006-04-04 Gelcore Llc Methods for forming aluminum-containing p-contacts for group III-nitride light emitting diodes
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006051065A2 (en) 2004-11-10 2006-05-18 Boehringer Ingelheim Pharma Gmbh & Co.Kg Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
CA2600601A1 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Anti-m-csf antibody compositions having reduced levels of endotoxin
CA2657953A1 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
WO2007021255A1 (en) * 2005-08-09 2007-02-22 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
WO2007075283A2 (en) 2005-12-06 2007-07-05 Amgen Inc. Polishing steps used in multi-step protein purification processes
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
EP2426145B1 (en) 2007-02-23 2017-01-18 Merck Sharp & Dohme Corp. Engineered anti-il-23p19 antibodies
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
PL2118300T3 (pl) 2007-02-23 2015-11-30 Prothena Biosciences Ltd Zapobieganie i leczenie synukleinopatii i amyloidozy
EP2522729A1 (en) 2007-03-02 2012-11-14 Boehringer Ingelheim Pharma GmbH & Co. KG Improvement of protein production
AU2008228823A1 (en) 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
PT2132230E (pt) 2007-03-22 2014-07-17 Genentech Inc Anticorpos apoptóticos anti-ige que se ligam ao ige ligado a membrana
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
KR101247418B1 (ko) 2007-12-21 2013-03-25 에프. 호프만-라 로슈 아게 항체 제형
DK2237803T3 (en) 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
PT2282758T (pt) * 2008-04-29 2019-02-12 Bioarctic Ab Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
US20120276019A1 (en) 2008-07-25 2012-11-01 Diamedica Inc. Tissue kallikrein for the treatment of parkinson's disease
AU2009328505B2 (en) * 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
AU2010281403B2 (en) 2009-07-28 2016-03-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
PL214940B1 (pl) 2009-07-31 2013-09-30 Lozano Platonoff Alberto Mechanizm wskaznikowy automatycznego aplikatora, zwlaszcza do insuliny
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011090720A2 (en) 2009-12-29 2011-07-28 Dr. Reddy's Laboratories Ltd Purification of proteins
EP2366714A1 (en) * 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2011127324A2 (en) 2010-04-08 2011-10-13 JN Biosciences, LLC Antibodies to cd122
BR112012030311A2 (pt) 2010-06-08 2017-01-24 Genentech Inc anticorpo
WO2011155607A1 (ja) 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
US8940300B2 (en) 2010-07-15 2015-01-27 Adheron Therapeutics, Inc. Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods
WO2012051147A1 (en) 2010-10-11 2012-04-19 Abbott Laboratories Processes for purification of proteins
EP2673635A4 (en) 2011-02-07 2015-08-12 Neotope Biosciences Ltd IMMUNOTHERAPY THROUGH APOE
US8619359B2 (en) 2011-04-27 2013-12-31 Howard Letovsky Electronic microscope filter
WO2012160536A1 (en) 2011-05-26 2012-11-29 Dr Reddy's Laboratories Limited Antibody purification
WO2012177997A1 (en) 2011-06-22 2012-12-27 The General Hospital Corporation Treatment of proteinopathies
RU2013155695A (ru) 2011-06-30 2015-08-10 Дженентек, Инк. Препараты антител против с-мет
SG10201604104PA (en) 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
US8609820B2 (en) 2011-10-28 2013-12-17 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
RU2665810C2 (ru) 2011-10-31 2018-09-04 Дженентек, Инк. Содержащие антитела составы
NZ629296A (en) 2012-01-27 2016-06-24 Prothena Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
RU2711552C2 (ru) 2012-08-29 2020-01-17 Ф. Хоффманн-Ля Рош Аг Шаттл для гематоэнцефалического барьера
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
JP6744856B2 (ja) 2014-04-08 2020-08-19 プロセナ・バイオサイエンシズ・リミテッド α−シヌクレインを認識する抗体を含む血液脳関門シャトル
US10084674B2 (en) 2015-09-09 2018-09-25 International Business Machines Corporation Virtual desktop operation and data continuity preservation

Also Published As

Publication number Publication date
RU2014121325A (ru) 2015-12-10
US9556259B2 (en) 2017-01-31
ES2669395T3 (es) 2018-05-25
ES2937409T3 (es) 2023-03-28
NZ625624A (en) 2016-06-24
JP6234511B2 (ja) 2017-11-22
HK1206637A1 (en) 2016-01-15
JP2018046836A (ja) 2018-03-29
DK3378535T3 (da) 2023-01-30
US11345749B2 (en) 2022-05-31
IL232264A0 (en) 2014-06-30
CN104334184A (zh) 2015-02-04
LT2771031T (lt) 2018-08-27
SMT202300048T1 (it) 2023-03-17
CN107880123A (zh) 2018-04-06
PL3378535T3 (pl) 2023-05-08
AU2016202622B2 (en) 2017-09-14
JP5775974B2 (ja) 2015-09-09
AU2017276296B2 (en) 2020-01-16
DK2771031T3 (en) 2018-05-28
EP2771031A1 (en) 2014-09-03
US20170240621A1 (en) 2017-08-24
SI3378535T1 (sl) 2023-04-28
EP2771031B1 (en) 2018-04-18
PE20141568A1 (es) 2014-11-21
EP2771031A4 (en) 2015-03-18
HK1201450A1 (en) 2015-09-04
AU2012328530A1 (en) 2014-06-26
MX370234B (es) 2019-12-06
US20220411486A1 (en) 2022-12-29
PH12014500938A1 (en) 2014-06-30
CO7020875A2 (es) 2014-08-11
US20130108546A1 (en) 2013-05-02
RU2743738C2 (ru) 2021-02-25
LT3378535T (lt) 2023-02-27
HUE061978T2 (hu) 2023-09-28
PT2771031T (pt) 2018-05-24
JP5960328B2 (ja) 2016-08-02
IL272615B (en) 2022-04-01
DK3378535T5 (da) 2024-09-30
RU2016101137A3 (uk) 2020-01-09
US20210040188A1 (en) 2021-02-11
IL232264B (en) 2020-02-27
BR112014010198A2 (pt) 2018-08-07
JP6592059B2 (ja) 2019-10-16
PT3378535T (pt) 2023-02-06
US20180201669A1 (en) 2018-07-19
US12528858B2 (en) 2026-01-20
JP2015502341A (ja) 2015-01-22
AU2016202622A1 (en) 2016-05-19
US8609820B2 (en) 2013-12-17
SI2771031T1 (en) 2018-08-31
MX2019014658A (es) 2020-02-07
JP2016208981A (ja) 2016-12-15
US20140275495A1 (en) 2014-09-18
MX2014005038A (es) 2015-03-09
CN104334184B (zh) 2017-12-29
SMT201800307T1 (it) 2018-09-13
EP3378535B1 (en) 2023-01-04
HUE037811T2 (hu) 2018-09-28
RU2016101137A (ru) 2018-11-16
KR20140081898A (ko) 2014-07-01
JP2015232002A (ja) 2015-12-24
WO2013063516A1 (en) 2013-05-02
US9884906B2 (en) 2018-02-06
US20200024336A1 (en) 2020-01-23
HRP20230065T1 (hr) 2023-03-03
EP3378535A1 (en) 2018-09-26
BR112014010198B1 (pt) 2022-12-06
AU2017276296A1 (en) 2018-01-18
PH12014500938B1 (en) 2019-01-16
CY1120398T1 (el) 2019-07-10
FI3378535T3 (fi) 2023-04-12
ZA201403864B (en) 2015-08-26
RS57315B1 (sr) 2018-08-31
RS63930B1 (sr) 2023-02-28
HK1252895A1 (zh) 2019-06-06
KR101600733B1 (ko) 2016-03-09
US10723792B2 (en) 2020-07-28
US10450369B2 (en) 2019-10-22
CL2014001073A1 (es) 2014-12-19
CA2853531C (en) 2020-03-10
MY165038A (en) 2018-02-28
PL2771031T3 (pl) 2018-09-28
IL272615A (en) 2020-03-31
SG11201401857WA (en) 2014-09-26
CA2853531A1 (en) 2013-05-02
HRP20180728T1 (hr) 2018-07-27

Similar Documents

Publication Publication Date Title
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
UA109633C2 (uk) Антитіло людини проти тканинного фактора
UA114891C2 (uk) ІЗОЛЬОВАНЕ АНТИТІЛО ЛЮДИНИ, ЯКЕ СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З АНГІОПОЕТИНПОДІБНИМ БІЛКОМ 3 ЛЮДИНИ (hАNGPTL3), ТА ЙОГО ЗАСТОСУВАННЯ
UA118441C2 (uk) Антитіло, що розпізнає альфа-синуклеїн
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
CY1119445T1 (el) Αντισωματα εναντι του ανθρωπινου gdf8
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
EA201190018A1 (ru) Миостатинсвязывающие белки
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
UA109658C2 (xx) Антитіло проти cgrp
UA112434C2 (uk) Антигензв'язувальний білок, який специфічно зв'язується з всма
CY1115572T1 (el) Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου
UA114712C2 (uk) Моноклональне антитіло, яке імуноспецифічно зв'язується з людським psgl-1, та його застосування
UA118646C2 (uk) Виділене антитіло, яке специфіічно зв'язується з онкостатином м (оm) людини
CY1115349T1 (el) Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου
CY1118254T1 (el) Αντισωματα toy βμρ-6
CY1118046T1 (el) Πρωτεϊνες δεσμευσης με αντιγονο ειδικες για το συστατικο ρ αμυλοειδους ορου
EA201300130A1 (ru) Способ лечения болезни альцгеймера
PE20141683A1 (es) Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs)
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3